Indivior PLC (LON:INDV) had its price objective dropped by investment analysts at Deutsche Bank AG from GBX 400 ($5.22) to GBX 395 ($5.16) in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 25.96% from the company’s current price.
A number of other equities research analysts also recently commented on the stock. Numis Securities Ltd restated a “buy” rating and issued a GBX 370 ($4.83) price objective on shares of Indivior PLC in a research report on Monday, September 26th. Jefferies Group raised their price objective on shares of Indivior PLC from GBX 330 ($4.31) to GBX 370 ($4.83) and gave the company a “buy” rating in a research report on Monday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 350 ($4.57) target price on shares of Indivior PLC in a report on Wednesday, August 17th. Royal Bank Of Canada increased their target price on shares of Indivior PLC from GBX 185 ($2.41) to GBX 325 ($4.24) and gave the company a “sector performer” rating in a report on Tuesday, August 9th. Finally, Morgan Stanley increased their target price on shares of Indivior PLC from GBX 280 ($3.65) to GBX 330 ($4.31) and gave the company an “overweight” rating in a report on Monday, August 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of GBX 345.71 ($4.51).
Indivior PLC (LON:INDV) opened at 313.60 on Tuesday. The firm’s market capitalization is GBX 2.26 billion. The company has a 50-day moving average price of GBX 318.51 and a 200-day moving average price of GBX 236.26. Indivior PLC has a 12-month low of GBX 126.60 and a 12-month high of GBX 365.00.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.